Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov-Dec;7(6):471-6.
doi: 10.1016/j.jash.2013.06.004. Epub 2013 Jul 23.

Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence

Larissa Grigoryan  1 , Valory N Pavlik  2 , David J Hyman  2
Affiliations
Randomized Controlled Trial

Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence

Larissa Grigoryan et al. J Am Soc Hypertens. 2013 Nov-Dec.

Abstract

Most studies on the prevalence and determinants of resistant hypertension (RH) do not account for white coat hypertension, medication non-adherence, or use of suboptimal treatment dosages. We studied the characteristics, drug combinations, and dosages of patients on at least three antihypertensives of different classes who had uncontrolled blood pressure on 24-hour ambulatory blood pressure monitoring and high medication adherence measured by electronic monitoring. The data were collected as part of the baseline measures of a hypertension control trial. Of 140 monitored primary care patients, all with uncontrolled office blood pressure, 69 (49%) were on at least three antihypertensives of different classes. Of these 69, 15 (22%) were controlled on ambulatory blood pressure monitoring, 20 (29%) were uncontrolled and non-adherent, leaving only 34 (49%) adherent to their medications and having uncontrolled ambulatory hypertension (uncontrolled RH). Thirty-one (91%) of the 34 uncontrolled RH patients were prescribed a diuretic, of which 24 were on hydrochlorothiazide 25 mg. Less than half of the patients on angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or calcium channel blocker were prescribed maximal doses of these agents. Half of the RH can be attributed to white coat effect and poor medication adherence, and all of the remaining patients were on apparently suboptimal drug combinations and/or dosages. Primary care physicians need to be educated regarding the optimal treatment of RH.

Keywords: Resistant hypertension; drug dosage; electronic monitoring; medication adherence; white-coat hypertension.

PubMed Disclaimer

Conflict of interest statement

No conflict of interests to declare.

Figures

Figure 1
Figure 1
Flow chart describing patient selection for analyses. ABPM, Ambulatory blood pressure monitoring; MEMS, Medication Event Monitoring System.
Figure 2
Figure 2
Drug combinations of 34 patients with uncontrolled resistant hypertension. aIncluding eight patients on diuretic/ACEi/β-blocker; two on diuretic/ARB/β-blocker; one on diuretic/CCB/β-blocker; one on ACEi/CCB/β-blocker; and one on ARB/β-blocker/direct vasodilator. bIncluding eight patients on a three-drug combination of diuretic/ACEi/CCB; two on four-drug combination of diuretic/ACEi/CCB/β-blocker; and two on a five-drug combination of diuretic/ACEi/CCB/β-blocker/α2-agonist. cIncluding one patient on a three-drug combination of diuretic/ARB/CCB; two on a four-drug combination of diuretic/ARB/CCB/β-blocker; and one on diuretic/ARB/CCB/ACEi/β-blocker. dIncluding two patients on diuretic/ACEi/ARB/β-blocker; one on diuretic/CCB/β-blocker/α2-agonist; and one on diuretic/ACEi/β-blocker/α2-agonist. ACEi, Angiotension-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium-channel blocker.
See this image and copyright information in PMC

Comment in

References

    1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–e526. - PubMed
    1. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. Journal Hypertens. 2001;19:2063–2070. - PubMed
    1. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57:1076–1080. - PubMed
    1. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898–902. - PubMed
    1. Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012;14:7–12. - PMC - PubMed

Publication types

MeSH terms